Bio-ionic liquid (BIL)-based ionogels have been researched for improved solubility, permeability, and bioavailability of poorly soluble drug/s. This study aimed to develop a thermoreversible ionogel for nose-to-brain delivery (NBD) of Tetrabenazine hydrochloride (TBZ), a BCS Class IV drug. Initially, a BIL-based micellar system of TBZ was developed using choline oleate ([Cho][Ole]) and decorated with Pluronic F-127 (PF-127). Further, the micellar system was formulated as a thermoreversible ionogel and optimized using central composite design (CCD). The resulting TBZ-[Cho][Ole]-PF-127, an optimized ionogel was evaluated for drug loading, particle size, polydispersity, zeta potential, morphology, pH, gelation behavior, mucoadhesive strength, and drug release (in vitro and ex vivo). All ionogel batches exhibited suitable physicochemical characteristics for NBD. TBZ-[Cho][Ole] micelles demonstrated a particle size of 94.23 ± 0.76 nm, whereas the optimized ionogel exhibited a size of 164.98 ± 0.89 nm, significantly smaller than the plain gel (247.65 ± 1.93 nm) at p < 0.05. The optimized ionogel showed a zeta potential of -38.12 ± 1.64 mV, drug loading of 37.92 ± 1.45%, and entrapment efficiency of 83.12 ± 2.53%. SEM and TEM studies confirmed that spherical micelles have the desired particle size. Ionogel in vitro and ex vivo evaluations divulged 1.37-fold and 1.42-fold enhancements in drug release and permeation, respectively, over plain gel (p < 0.05), following zero-order kinetics. Short-term stability studies further confirmed the robustness of the formulation. Conclusively, the ionogel demonstrated improved delivery of TBZ, opening up the vista of BIL and ionogel customizability for NBD for diverse drug/s used in the management of neurological disorders.